Clinical Trial Update: Bortezomib Plus Rituximab for EBV+ PTLD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib plus rituximab for EBV-positive post-transplant lymphoproliferative disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disease

Drugs mentioned

• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Post-transplant Lymphoproliferative Disease, Solid Organ Transplant | Phase 2 | Status: COMPLETED | Results posted: 2018-02-15